Drugmakers are racing to deliver more dystrophin to muscle cells than today's approved therapies can manage
May 7th, 2026: Entrada releases first human efficacy dataNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Boys born with Duchenne muscular dystrophy typically lose the ability to walk before their teens and rarely live past 30. The first drugs designed to slow that decline reached the market in 2016, but they restore less than 1% of normal dystrophin, the muscle protein patients are missing. A decade later, a new wave of biotech companies is trying to deliver far more of that protein into muscle cells using engineered molecular shuttles.
On May 7, 2026, Entrada Therapeutics released the first human efficacy data for one such shuttle — its Endosomal Escape Vehicle platform — in patients with the exon-44 form of the disease. The readout matters because Entrada and rival Avidity Biosciences are both betting that better delivery technology will turn exon-skipping from a marginal therapy into one that meaningfully changes the disease's trajectory.
Why it matters
Better delivery technology could turn Duchenne from a fatal childhood disease into a manageable one for thousands of boys worldwide.
Gene Therapy Gives Hope for a Duchenne Cure
Ann & Robert H. Lurie Children's Hospital of Chicago
A.I. technology bringing hope for muscular dystrophy ...
A Current Affair
PPMD 2025 Annual Conference: Day 2 - Dystrophin: The ...
Parent Project Muscular Dystrophy
Videos from YouTube.
Exploring all sides of a story is often best achieved with Play.
Fictional AI pastiche — not real quote.
"It warms my heart to see men of science apply themselves not to the vanity of courts, but to the deliverance of suffering children — for what nobler experiment hath any philosopher conducted than one whose instrument is hope and whose reward is a boy who keeps his legs beneath him another decade."
Your progress in this debate will be lost.
Choose one persona for each side of the debate
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Make your prediction before the referee scores
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
Boston biotech developing cyclic cell-penetrating peptides that ferry oligonucleotide drugs into the inside of muscle cells.
San Diego biotech that conjugates oligonucleotide drugs to antibodies targeting muscle-cell receptors.
Owns three of the four approved exon-skipping drugs and the only approved Duchenne gene therapy, Elevidys.
United States regulator that approves new drugs and oversees clinical trials.
Entrada announces topline Cohort 1 results from the Phase 1/2 ELEVATE-44-201 study, the first efficacy readout for the EEV platform in Duchenne patients.
After three deaths from acute liver failure, FDA imposes a boxed warning on Elevidys and limits its use to ambulatory patients aged four and older.
Del-zota produces about 25% of normal dystrophin and near-normal creatine kinase in DMD patients. FDA grants Breakthrough Therapy designation, and Avidity plans an accelerated-approval filing.
After 26 months, FDA authorizes Entrada to begin a Phase 1b multiple ascending dose trial of ENTR-601-44 in adult Duchenne patients in the United States.
Avidity Biosciences announces dystrophin restoration with del-zota in early trial data, validating its antibody-oligonucleotide conjugate platform.
FDA grants accelerated approval to Elevidys, a one-time gene therapy that delivers a shortened dystrophin gene using a viral vector.
FDA places a clinical hold on Entrada's investigational new drug application for ENTR-601-44, blocking US patient trials. Entrada moves early studies to the United Kingdom.
Entrada Therapeutics completes its initial public offering on Nasdaq, raising capital to advance its Endosomal Escape Vehicle platform into human trials.
FDA grants accelerated approval to Sarepta's eteplirsen despite advisors voting against it, citing dystrophin restoration of less than 1% as a surrogate marker.
Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.
Cohort 1 produces double-digit dystrophin restoration, in the same range as Avidity's 25% benchmark. Entrada continues into higher-dose cohorts and positions for accelerated approval roughly 18 months behind Avidity. Both EEV and antibody-conjugate platforms become validated for broader exon-skipping franchises and other muscle diseases.
Cohort 1 produces only single-digit dystrophin at the 6 mg/kg dose, below internal projections. Entrada points to its 12 mg/kg and higher cohorts, due later in 2026, as the real test. The stock falls sharply but the program continues, with the higher-dose readouts becoming the make-or-break catalyst.
The trial reveals liver enzyme elevations or other adverse events that echo earlier concerns about cell-penetrating peptide chemistry. Given the Elevidys precedent, FDA pauses dosing or requires additional safety monitoring. The setback would not end the EEV platform but would add years to its timeline.
Cohort 1 produces dystrophin restoration well above the Avidity benchmark, suggesting the EEV platform delivers more drug to muscle than antibody conjugates. The result would attract a large-pharma acquirer and shift competitive dynamics across the exon-44, exon-45, exon-51 and exon-53 programs Entrada also has in early development.
FDA approved Sarepta's eteplirsen for Duchenne despite an advisory committee voting 7-3 that the data did not show effectiveness. The approval was based on dystrophin restoration of less than 1% in 12 patients, with no functional benefit demonstrated. FDA reviewer Ellis Unger called the evidence inadequate; Commissioner Robert Califf overruled him.
Sarepta priced eteplirsen at roughly $300,000 per patient per year. Patient advocates celebrated, but mainstream physicians questioned whether the drug worked.
The decision established dystrophin restoration as an acceptable surrogate marker for accelerated approval, paving the way for three more exon-skipping drugs and the entire next generation of EEV and antibody-conjugate programs.
Today's regulatory pathway for ENTR-601-44 and del-zota exists because of the eteplirsen precedent. The low bar set in 2016 is exactly what new entrants are trying to dramatically clear with better delivery technology.
FDA approved Biogen's Spinraza, an antisense oligonucleotide injected into the spinal canal, for spinal muscular atrophy. The drug increased survival motor neuron protein production and produced dramatic motor function improvements in infants who had previously faced near-certain death.
Spinraza became a multi-billion-dollar drug and made spinal muscular atrophy the textbook example of how oligonucleotide therapy can transform a fatal pediatric neuromuscular disease.
The success encouraged investment across oligonucleotide platforms targeting Duchenne, myotonic dystrophy, and other rare neuromuscular conditions. It also raised expectations: investors and patients now ask why Duchenne drugs cannot match Spinraza's effect size.
Spinraza shows what is possible when an oligonucleotide reaches its target tissue at sufficient concentration. The next-generation Duchenne race is essentially an attempt to replicate that delivery success in a much harder tissue: skeletal muscle.
FDA imposed a black-box warning on Sarepta's Elevidys gene therapy after three patients died of acute liver failure following infusion. The agency narrowed the label to ambulatory patients aged four and older, removing the non-ambulatory indication granted just a year earlier. Sarepta cut roughly 500 jobs.
Elevidys revenue projections fell sharply. Sarepta's stock dropped, and patient families faced new uncertainty about the only approved gene therapy for the disease.
The setback opens commercial space for exon-skipping competitors and increases pressure on FDA to scrutinize new Duchenne approvals. It also reminds the field that one-time gene therapies carry irreversible risks that repeated-dose oligonucleotides do not.
The Elevidys warning shifted the competitive landscape that Entrada and Avidity now occupy. With gene therapy facing safety scrutiny, the next-generation oligonucleotide approach has both a bigger market opportunity and a more cautious regulator to navigate.